Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Stomatitis 2 Mucositis 2 Mouth Neoplasms 2 Head and Neck Neoplasms 2 Neuroendocrine Tumors 1 Lung Neoplasms 1 Colorectal Neoplasms 1 Cholangiocarcinoma 1 Carcinoma, Squamous Cell 1 Carcinoma, Small Cell 1 Carcinoma, Ovarian Epithelial 1 Carcinoma, Non-Small-Cell Lung 1

Interventions

Bevacizumab 234 Fluorouracil 220 Oxaliplatin 216 Irinotecan 215 Leucovorin 199 Capecitabine 153 Cetuximab 146 Panitumumab 70 Folfox protocol 51 regorafenib 43 Radiotherapy 38 pembrolizumab 37 IFL protocol 36 HMPL-013 36 trifluridine tipiracil drug combination 32 Nivolumab 32 Drug Therapy 26 Neoadjuvant Therapy 24 Trifluridine 18 Celecoxib 18 tislelizumab 17 XELOX 17 sintilimab 16 Trastuzumab 16 durvalumab 15 atezolizumab 15 aflibercept 15 Chemotherapy, Adjuvant 15 Biopsy 15 apatinib 14

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Colorectal Neoplasms × RRx-001 × Clear all

NCT02096354 2024-10-15

ROCKET

EpicentRx, Inc.

Phase 2 Completed

62 enrolled 14 charts

Gastrointestinal

Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡